Pfizer Inc. said Thursday it is halting a late-stage study of its highly anticipated blood thinner apixaban, due to dangerous bleeding among patients with a history of heart disease.
- Airports consider congressman's call to ditch TSA- AP
- Dell 3Q net income more than doubles- AP
- Airlines: Rolls modified engine before blowout- AP
- General Motors shares jump on Wall Street return- AP
- First day trading of GM deemed a success- AP
- How GM's return played in 3 cities with a stake- AP
- Stocks jump as worries over Ireland ease; GM pops- AP
- More than half leave Obama mortgage-aid program- AP